News coverage about Ovid Therapeutics (NASDAQ:OVID) has trended somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ovid Therapeutics earned a news sentiment score of 0.09 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.8958508176393 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Ovid Therapeutics (OVID) traded up $0.09 during trading hours on Thursday, hitting $10.42. The company had a trading volume of 64,900 shares, compared to its average volume of 63,283. Ovid Therapeutics has a fifty-two week low of $5.28 and a fifty-two week high of $15.93.

Ovid Therapeutics (NASDAQ:OVID) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.16. analysts anticipate that Ovid Therapeutics will post -4.08 EPS for the current year.

Separately, Zacks Investment Research upgraded Ovid Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a report on Thursday, November 16th. Five analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and a consensus target price of $19.33.

COPYRIGHT VIOLATION WARNING: “Ovid Therapeutics (OVID) Earning Somewhat Positive News Coverage, Report Shows” was first posted by Daily Political and is owned by of Daily Political. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist.

Insider Buying and Selling by Quarter for Ovid Therapeutics (NASDAQ:OVID)

Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with's FREE daily email newsletter.